Igantibe

Human Hepatitis B Immunoglobulin, the active ingredient in Igantibe, is an immunoglobulin presented as an injectable solution for intramuscular use. It provides passive immunity to prevent hepatitis B infection after exposure and to protect newborns of HBsAg‑positive mothers.

GNH USA supplies Igantibe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution, including cold‑chain logistics for biologic products and timely delivery.

Igantibe, a hepatitis B immune globulin, is used within the hepatitis B prevention pathway. - Post‑exposure prophylaxis: Provides immediate passive immunity to reduce the risk of hepatitis B infection after known exposure. - Newborn protection: Prevents vertical transmission of hepatitis B from HBsAg‑positive mothers to their infants. - Liver transplant prophylaxis: Helps prevent recurrent hepatitis B infection in recipients of liver transplants from infected donors. - Chronic HBV carrier management: Offers short‑term protection for chronic carriers undergoing invasive procedures.

Igantibe may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Injection site pain: Local soreness or tenderness at the injection site. - Fever: Temporary rise in body temperature after the dose. - Headache: Mild to moderate headache reported by some patients.

Serious or Rare Side Effects: - Anaphylaxis: Severe allergic reaction that may cause airway obstruction and shock. - Serum sickness: Rash, joint pain, and fever due to immune complex formation. - Hemolysis: Red blood cell destruction that can lead to anemia and jaundice.

Before using Igantibe, several precautions should be observed to ensure safety and efficacy. - Screen for HBV status: Verify that the patient is HBsAg‑negative before prophylactic use. - Assess hypersensitivity: Do not administer to individuals with known allergy to human immunoglobulins. - Monitor after injection: Observe the patient for at least 30 minutes for any immediate adverse reactions. - Evaluate pregnancy risk: Use only when the potential benefit justifies the potential risk to the fetus. - Avoid concurrent live vaccines: Delay live‑attenuated vaccinations for at least four weeks after administration. - Store at 2-8°C: Keep refrigerated, protect from light, and do not freeze or shake the product.

Igantibe can interact with certain medicines or vaccines, requiring careful management.

Major Interactions (Avoid): - Live attenuated vaccines: Co‑administration may reduce vaccine efficacy and increase risk of adverse events. - Immunosuppressive therapy: Concurrent high‑dose steroids or biologics may diminish the protective effect of the immunoglobulin.

Moderate Interactions (Monitor Closely): - Blood products containing anti‑HBs: May lead to immune complex formation and increase risk of serum sickness. - Anticoagulants: Intramuscular injection can raise the chance of local hematoma; monitor coagulation status. - Renal‑impairing drugs: May exacerbate rare renal side effects; assess kidney function regularly.